NUWE NUWELLIS INC

Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services

Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services

MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services.

Nuwellis Chairman and CEO John Erb commented, “We believe CORE IR’s integrated communications approach will enable us to more effectively articulate our value proposition to investors, partners, and key stakeholders. As we continue to expand our presence across the medical device and diagnostics markets, we see significant opportunities to drive long-term value. We look forward to working closely with CORE IR to communicate our growth strategy and highlight the opportunities ahead as we advance our trajectory.”

CORE IR will focus on expanding market awareness for Nuwellis, conveying Nuwellis’ solutions, business model, and development plans to target audiences, and providing public relations and digital communications services. CORE IR, a boutique Investor and Public Relations, Digital communications, and strategic advisory firm, specializes in leveraging effective investment, growth, and exposure strategies for small to mid-sized publicly traded and privately held companies through an integrated approach to relationship development and corporate communications.

“CORE IR is a great fit for Nuwellis as the breadth of our team’s experience and capabilities will serve the Company’s communications goals utilizing tailored strategies toward driving market awareness, expanding outreach, and engaging with relevant audiences. We look forward to a strong strategic partnership that facilitates consistent targeted communications through our multi-channel strategy,” added CORE IR’s Co-Founder and President Scott Gordon.

About CORE IR

CORE IR is comprised of senior market and practice leaders with expertise in institutional and retail investor relations, integrated public relations, corporate and digital communications, and capital markets advisory services. CORE IR provides proprietary integrated investor relations, public relations, and digital communications solutions that yield targeted exposure for small to mid-sized companies. For more information, please visit .

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company committed to delivering solutions for patients with cardiorenal conditions. The Company develops solutions designed to support patient care through monitoring, therapy, and data-informed clinical decision-making across acute and chronic care settings. Nuwellis’ portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions, with a focus on safety, precision, and scalability across patient populations. For more information, visit .

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2026 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.

For further information, please contact:

Investor Relations:

Media Contact:

CORE PR



EN
09/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE

Nuwellis Engages CORE IR for Public Relations, Shareholder Communicati...

Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services MINNEAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces it has retained CORE IR, a leading investor relations, public relations, and strategic advisory firm, to assist the Company with public relations, shareholder communications, and social media management services. Nuwellis Chairman and CEO John Erb commented, “We believe CORE IR’s integ...

 PRESS RELEASE

Nuwellis Strengthens Commercial Infrastructure with New South Texas Te...

Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory Strategic expansion of field coverage enhances hospital engagement and increases access to Aquadex® therapy across the region MINNEAPOLIS, April 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the creation of a dedicated South Texas commercial territory as part of its ongoing effort to strengthen field engagement in key U.S. hospital markets. South Texas is a significant healthc...

 PRESS RELEASE

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. R...

Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone Pediatric footprint expands to 47 centers nationwide, including six of the nation’s top 10 children’s hospitals MINNEAPOLIS, March 31, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces continued momentum in its pediatric category, which is now the Company’s largest and fastest-growing category and represents approximately 50% of total U.S. revenue. “Our pedi...

 PRESS RELEASE

Nuwellis Completes Acquisition of Rendiatech

Nuwellis Completes Acquisition of Rendiatech Adds automated kidney function monitoring technology to support earlier clinical insight and strengthen Nuwellis’ fluid management platform MINNEAPOLIS, March 17, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the completion of its previously announced acquisition of Rendiatech, Inc., an Israeli-based developer of automated kidney function monitoring technology designed to support clinical decision-making in critic...

 PRESS RELEASE

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial R...

Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Fa...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch